PATENT CLAIM ANALYSIS

Application Number: 16020276
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["530", "388240"]

Abstract:
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn.

Claim (Index 6):
An isolated nucleic acid encoding a chimeric or humanized anti-histone H3 antibody or antigen-binding fragment thereof, wherein the chimeric or humanized anti-histone H3 antibody or antigen-binding fragment thereof comprises the heavy chain CDR sequences CDR1 (SYWMH, SEQ ID NO:100), CDR2 (NIDPSDSETHYNQKFKD, SEQ ID NO:101) and CDR3 (EKITDDYNYFDY, SEQ ID NO:102) and the light chain CDR sequences CDR1 (RASESVDSYGNSFMH, SEQ ID NO:103), CDR2 (HASNLES, SEQ ID NO:104) and CDR3 (QQNNEDPLT, SEQ ID NO:105).

Metadata:
- Claim Count in Document: 35.0
- Percentile: 94.0
- Lexical Diversity: 1.89362
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15487747', '14620315', '14180646', '15005596', '15887488']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8094888187282498
- 35 USC 102 Novelty (BERT): 0.6872873943744229
- Combined Prediction Score: 0.7972686762928671
- Mean Citation Score: 724.1390160000003
- Max Citation Score: 734.35834
- Similarity Product: 680.7794977076447

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test